anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a prescription medicine and a preparation method thereof, which are suitable for treating grey hair and white hair and alopecia in young and strong years, and the prescription medicine has the advantages of simple formula, easy preparation process, carefully selected natural raw materials, nutrition of hair sacs, hairdressing and hair nourishing. Is beneficial to the health of human bodies, and has the following advantages that the bewildness of white hair and alopecia can be avoided in early years of young and strong: 1. aiming at the situation that only tonifying qi and blood and nourishing liver and kidney are paid attention to in the past of young and strong white hair and alopecia, the condition that the nutrition supply of hair sacs is not good due to blockage and the like is neglected, and the problem that the effect is poor after a part of patients use the existing method for tonifying liver and kidney and qi and blood in clinic is solved. 2. The prescription is developed by the professor Chen Rongzhong of the applicant and the team thereof for decades and  force, and has definite and reliable curative effect by comparing the prescription with the prescription. 3. The selected medicine is safe and nontoxic, treats both principal and secondary aspect of disease by an oral administration method, also avoids the defect of skin and hair follicle stimulation when the medicine is used outside, avoids the side effects of western medicines which are taken inside and outside, does not find toxic or side effects after long-term use, and has lasting curative effect.
1. Inspect eptifibatide injection for particulate matter and discoloration prior to administration, whenever solution and container permit. 
  2. May administer eptifibatide injection in the same intravenous line as alteplase, atropine, dobutamine, heparin, lidocaine, meperidine, metoprolol, midazolam, morphine, nitroglycerin, or verapamil. Do not administer eptifibatide injection through the same intravenous line as furosemide. 
  3. May administer eptifibatide injection in the same IV line with 0.9% NaCl or 0.9% NaCl/5% dextrose. With either vehicle, the infusion may also contain up to 60 mEq/L of potassium chloride. 
  4. Withdraw the bolus dose(s) of eptifibatide injection from the 10 mL vial into a syringe. Administer the bolus dose(s) by IV push. 
  5. Immediately following the bolus dose administration, initiate a continuous infusion of eptifibatide injection. When using an intravenous infusion pump, administer eptifibatide injection undiluted directly from the 100 mL vial. Spike the 100 mL vial with a vented infusion set. Center the spike within the circle on the stopper top. 
  6. Discard any unused portion left in the vial. 



Administer eptifibatide injection by volume according to patient weight (see Table 1).
Receptors are disclosed that are antibodies that exhibit a binding affinity for an immune complex of a monoepitopic antigen and an antibody for such antigen that is substantially greater than the binding affinity for the monoepitopic antigen or the antibody for the monoepitopic antigen apart from the immune complex. In one embodiment the receptors are antibodies prepared against an affinity-labeled complex of an antigen and an antibody for the antigen. Normally, the monoepitopic antigen has a molecular weight less than 1500 and is an organic compound. The antibodies of the present invention find use in a method for determining a monoepitopic antigen in a sample suspected of containing such antigen. The method comprises forming an immune sandwich complex comprising the monoepitopic antigen or an analog thereof, a first monoclonal antibody that binds to the monoepitopic antigen, and a second monoclonal antibody that is an antibody of the present invention and detecting the immune sandwich complex. Compositions of matter and kits for use in conducting an assay in accordance with the invention as well as methods for producing the above receptors are also disclosed.
Kidney transplantation is the preferred gold standard modality of treatment for kidney failure. Bone disease after kidney transplantation is highly prevalent in patients living with a kidney transplant and is associated with high rates of hip fractures. Fractures are associated with increased healthcare costs, morbidity and mortality. Post-transplant bone disease (PTBD) includes renal osteodystrophy, osteoporosis, osteonecrosis and bone fractures. PTBD is complex as it encompasses pre-existing chronic kidney disease-mineral bone disease and compounding factors after transplantation, including the use of immunosuppression and the development of de novo bone disease. After transplantation, the persistence of secondary and tertiary hyperparathyroidism, renal osteodystrophy, relative vitamin D deficiency and high levels of fibroblast growth factor-23 contribute to post-transplant bone disease. Risk assessment includes identifying both general risk factors and kidney-specific risk factors. Diagnosis is complex as the gold standard bone biopsy with double-tetracycline labelling to diagnose the PTBD subtype is not always readily available. Therefore, alternative diagnostic tools may be used to aid its diagnosis. Both non-pharmacological and pharmacological therapy can be employed to treat PTBD. In this review, we will discuss pathophysiology, risk assessment, diagnosis and management strategies to manage PTBD after kidney transplantation.
The present invention pertains to the technical field of medicine in particular relates to Chinese traditional medicine Kidney Tea removal of urinary calculus complex prescription and preparation used for preventing and curing urinary calculus, removing urinary calculus, promoting urination and anti-inflammatory. The Chinese traditional medicine complex prescription mainly comprises kidney tea and herba lysimachiae. In mixture ratios of components, the prescription comprises 1 to 10 times of kidney tea, and 1 to 10 times of herba lysimachiae and comprises 10 to 180g of kidney tea and 10 to 180g of herba lysimachiae in weight ratio. Various convenient medicament forms are made according to conventional extraction and preparation technology of the Chinese traditional medicine kidney tea urinary calculus removal complex prescription. Experiments of the Chinese traditional medicine kidney tea urinary calculus removal complex on animals indicate that the medicine has the advantages of reducing fever, eliminating dampness, removing urinary calculus, promoting urination and resisting inflammation. The medicine is used for preventing and curing the urinary calculus. The urinary calculus can be effectively discharged from body within a relatively short time after the medicine is taken by patients. Raw materials for the Chinese traditional medicine contained in the Chinese traditional medicine kidney tea urinary calculus removal complex prescription and the preparation are broad in source, scientific in processing, scientific in operation, high in effective ingredient of the finished product and convenient in use.
A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to  Borrelia burgdorferi  ( B. burgdorferi ) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with  B. burgdorferi . Mammals that have early, intermediate or chronic  B. burgdorferi  infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant  B. burgdorferi  antigens and compositions that contain them are also provided.
The invention provides a miRNA marker of non-alcoholic fatty liver disease and application thereof, which can be used for judging the non-alcoholic fatty liver disease. The miRNA marker is selected from: miRNA-1911 primary miRNA, miRNA-1911 precursor miRNA, and mature miRNA-1911; the miRNA-1911 primary miRNA is cleaved and expressed as mature miRNA-1911 within a human cell; the miRNA-1911 precursor miRNA is cleaved and expressed in human cells as mature miRNA-1911. The invention discovers that the miRNA marker miRNA-1911 can be used for judging the process and the severity of the non-alcoholic fatty liver disease for the first time. The test proves that the miRNA-1911 can effectively distinguish the nonalcoholic fatty liver sample from the normal sample. On the basis, the miRNA-1911 can also be used for preparing medicines for inhibiting the non-alcoholic fatty liver. The invention provides a new method for developing the non-alcoholic fatty liver disease at the molecular level in clinic, and provides a new drug target for the treatment of the non-alcoholic fatty liver disease.
The invention relates to a cardiac neurosis treating traditional Chinese medicine and a preparation method thereof, wherein the technical scheme comprises 18 parts of sagittaria trifolia var. sinensis, 13 parts of fallopia multiflora (thunb.) harald, 13 parts of angelica sinensis, 18 parts of tuckahoe, 18 parts of fried ziziphus jujuba mill.var.spinosa, 12 parts of panax notoginseng, 12 parts of atractylodes macrocephala, 17 parts of ephedra sinica stapf, 13 parts of milkvetch root, 13 parts of rhizoma corydalis, 13 parts of root of dadvid bushclover, 13 parts of eucommia ulmoides, 17 parts of leech, 17 parts of donkey-hide glue, 13 parts of fallopia multiflora (thunb.) harald, 17 parts of santalum album, and 13 parts of raw milkvetch root. The preparation method comprises: taking the bulk drugs in the formula, adding a proper amount of water, decocting for about 40 min with mild fire, and filtering to removing the drug reside so as to prepare the decoction. According to the present invention, the clinical trial results prove that the cardiac neurosis treating traditional Chinese medicine has characteristics of no toxic-side effect, significant treatment effect, high cure rate and no adverse reaction, and can significantly improve patient internal organ functions, especially patient cardiac functions.
This term refers to a situation where the lateral and longitudinal control of the driving are delegated to the automated assistive technology. It consists of a level of automatisation that today is possible to put into application and which often is referred to by the name "Highly Automated Driving" (Navarro, 2018). In this case, the driver is no longer the one who physically ensures the lateral and longitudinal control of the vehicle, but instead supervises the actions of the automated assistive technology.
BACKGROUND: Neonatal sepsis, a perilous medical situation, is typified by the malfunction of organs and serves as the primary reason for neonatal mortality. Nevertheless, the mechanisms underlying newborn sepsis remain ambiguous. Programmed cell death (PCD) has a connection with numerous infectious illnesses and holds a significant function in newborn sepsis, potentially serving as a marker for diagnosing the condition.
METHODS: From the GEO public repository, we selected two groups, which we referred to as the training and validation sets, for our analysis of neonatal sepsis. We obtained PCD-related genes from 12 different patterns, including databases and published literature. We first obtained differential expressed genes (DEGs) for neonatal sepsis and controls. Three advanced machine learning techniques, namely LASSO, SVM-RFE, and RF, were employed to identify potential genes connected to PCD. To further validate the results, PPI networks were constructed, artificial neural networks and consensus clustering were used. Subsequently, a neonatal sepsis diagnostic prediction model was developed and evaluated. We conducted an analysis of immune cell infiltration to examine immune cell dysregulation in neonatal sepsis, and we established a ceRNA network based on the identified marker genes.
RESULTS: Within the context of neonatal sepsis, a total of 49 genes exhibited an intersection between the differentially expressed genes (DEGs) and those associated with programmed cell death (PCD). Utilizing three distinct machine learning techniques, six genes were identified as common to both DEGs and PCD-associated genes. A diagnostic model was subsequently constructed by integrating differential expression profiles, and subsequently validated by conducting artificial neural networks and consensus clustering. Receiver operating characteristic (ROC) curves were employed to assess the diagnostic merit of the model, which yielded promising results. The immune infiltration analysis revealed notable disparities in patients diagnosed with neonatal sepsis. Furthermore, based on the identified marker genes, the ceRNA network revealed an intricate regulatory interplay.
CONCLUSION: In our investigation, we methodically identified six marker genes (AP3B2, STAT3, TSPO, S100A9, GNS, and CX3CR1). An effective diagnostic prediction model emerged from an exhaustive analysis within the training group (AUC 0.930, 95%CI 0.887-0.965) and the validation group (AUC 0.977, 95%CI 0.935-1.000).
PURPOSE: A remote patient monitoring system and a method thereof are provided to enable a user to take medical service in a remote place using an existing medical equipment. CONSTITUTION: ID information of a medical equipment and treatment data are received from the medical equipment(S430). A user identification information is inputted from an outside(S440). The ID information of the medical equipment and the user ID information is compared with each other(S445). The treatment data compares the difference between the user ID information receiving time and the user ID information inputting time(S455). If the time difference is smaller than the reference time, the treatment data by the user ID information is transmitted to an EMR(Electronic Medical Record) server.
PURPOSE: To provide an adhesive film bandage which is suitably used for the protective cover for covering a part of friction vessicle, by including an embossed elastic film of a specific thickness, coating one surface with the pressure sensitive adhesive, and specifying the water vapor permeability and the frictional coefficient on the surface not having the adhesive. CONSTITUTION: A thin film bandage used for prevention and medical treatment of the friction bulla of a skin, comprises an embossed elastic film of which one side is coated with a pressure sensitive adhesive of medical treatment quality. The film has about 0.5 through 10.0mil of thickness, and has at least 100g/ m<2> /day of the water vapor permeability. The embossing is performed for reducing the effective surface area at the side not including the adhesive, and lowering the frictional coefficient of the surface by less than about 1.0. The embossing further increases the adaptability of the film to an irregular surface, and reduces the tendency that the film is distorted or rolled up during the use, thereby the bandage can be held on a fixed position on the skin with high stability. The film bandage is properly made of an elastomer polyurethane or a polyester polymer.
118,435. Willcocks, E. W. Aug. 24, 1917. Making-up material for threatrical use. - Greast paints consist of a mixture of a fattv base, such as hard and soft white paraffins, with a pigment prepared by treating an insoluble white powder with a solution of a colouring matter which is insoluble in the fatty base and then drying and re-powdering the product. Specified insoluble powders are starch, chalk, kaolin, zinc oxide, and mixtures thereof. Specified aniline dyes for use as the colouring matter are victoria scarlet, methylene blue, and auramine. Various tints may be prepared by mixing the dye solu'- tions or the dyed powders, with or without the addition of a black dye or powder. The proportion of dye to white powder may be varied', but the proportion of the powder to the fatty base is standardized.
The standard re-irradiation regimen for head and neck cancer patients treated at the Oslo University Hospital is 1.5 Gy twice daily during 4 weeks with a total dose of 60 Gy.

In this study the radiotherapy is planned using 18F-FDG PET/CT making one experimental "dose-painting by contours" SIB (simultaneous integrated boost) plan with a maximum point dose of 75 Gy. The participants will be given 65 Gy and 70 Gy minimum doses to two GTVs inside the conventional GTV (60 Gy). GTV_65Gy and GTV_70Gy are determined from the SUV values from the 18F-FDG PET/CT according to the formula proposed by the Ghent group (Van der Straeten et al, R\&O -06). It is expected to keep the level of normal tissue side-effects within or slightly above the level of conventional radiotherapy (i.e. maximum dose of 60 Gy). In addition to the routine follow-up, the participants will be examined with 18F-FDG PET/CT 6 months after inclusion (4 1/2 months after end of radiotherapy) and HRQL measurements.
Sodium Acetate for Injection, USP CONCENTRATE must be diluted before use. To avoid sodium overload and water retention, infuse sodium containing solutions slowly. Do not use unless solution is clear and seal is intact.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
The invention relates to medical preparations of phytogenic origin, in particular, to a method for preparing a medicament from Salsola collina Pall. Ex Spreng having cytoprotective activity and can be used in medicine in treating liver diseases and bile-excreting tract.The claimed invention is aimed at preparing a new cytoprotective medicament from Salsola collina Pall. Ex Spreng.The proposed method comprises extraction of lipophilic substance from Salsola collina Pall. Ex Spreng with crushing rate 2 ± 0.1 mm using extraction method by liquefied carbon dioxide (CO) at 63±1 atm. pressure, at 23°±0.5°C, extraction time -20 hrs, extraction of target product, flavonoid sum, 60% ethanol, with subsequent freeze drying of substance at +65°C, pressure at least 5 atm, during 24 hrs. The dried product is further milled to powder-like state and combined with auziliarysubstances to obtain cytoprotective medicament.The preparation has highly medical-prophylaxis effect in treating liver diseases and bile-excreting tract compared ro known preparations “Legalon”, Essenciale”, “Carcyl”.
Participants in the control arm will follow the standard rehabilitation programme at a frequency of ideally 2 times a week. To align with the duration of the intervention arm, participants in the control arm will also perform an additional 15 minutes of exercises (following standard care of the site).
This Phase 1 clinical trial is a multicenter, double-blind, single ascending dose trial evaluating safety in up to a total of 48 participants across up to 6 dose cohorts, 5 planned and 1 to be determined if an additional dose group is required. Each cohort will include 8 participants (6 active, 2 placebo) who will receive a single dose of either PNT001 or placebo. Within each cohort a sentinel group of 2 participants (1 active, 1 placebo) will be enrolled to evaluate safety and tolerability before enrolling the full cohort. If there are no safety concerns (as determined by the data and safety monitoring board \[DSMB\]), the remaining 6 participants (randomized as 5 active, 1 placebo) will be enrolled. This process will be followed for all additional cohorts.

After screening, and laboratory assessments at Day -1, eligible participants will be admitted to the research unit on Day 1 (or Day -1 at Investigator's discretion), where they will remain for three (or four) nights with standardized meals provided during their inpatient stay. On Day 1, participants will be randomized to receive either active drug or placebo. Study medication will be administered as a single i.v. infusion over 30 minutes (up to 60 minutes for doses greater than 2,700 mg), followed by collection of safety, tolerability, and PK data over 16 weeks. Participants will be discharged on Day 4 and will return for an outpatient study visit on Day 5 (may be phone or clinic visit), and to the study site on Days 7, 14, 28, 42, 56, 70, 84, 98, and 112.
Prostate cancer is the most frequent malignant tumor in men worldwide. Prostate-specific membrane antigen (PSMA), is a surface molecule specifically expressed by prostate tumors which was shown to be a valid target for radiotherapy. 177Lu-PSMA-617, a urea-based compound, provide an effective target for the treatment of metastatic castration-resistant prostate cancer. However, a major problem in the therapeutic use of 177Lu-PSMA-617 has been its short half-life and fast rate of clearance. The investigators designed and synthesized a new radiopharmaceutical, named 177Lu-PSMA-EB-01. EB（Evans Blue）can bind to albumin to slow down its plasma clearance rate, thereby increasing tumor accumulation and reducing the total dosage of Lu-177. Hence, EB-PSMA-01 may be an option for consideration due to limited supply of Lu-177, by which more patients may be benefited by this version of 177Lu-EB-PSMA-01. This study was designed to investigate the safety, dosimetry and preliminary effects of 177Lu-EB-PSMA-01 in patients with metastatic castration resistant prostate cancer.
Patients will be stratified into BMI≥28kg/m2 group and BMI\<28kg/m2 group. Patients in BMI≥28kg/m2 or BMI\<28kg/m2 group were randomly assigned (1:1) to GnRHa+letrozole group or MA/MPA group.Patients assigned to MA/MPA group will receive MA/MPA (160 mg oral MA daily or 500 mg oral MPA daily).Then every 3 months, an hysteroscopy will be used to evaluate the endometrial condition, and the findings will be recorded.
As the main active ingredient of Astragalus, Astragaloside IV (AS-IV) can ameliorate pulmonary fibrosis. In this experiment, we studied how AS-IV reduces idiopathic pulmonary fibrosis (IPF). Bleomycin (BLM) or TGF-β1 was treated in mice or alveolar epithelial cells to mimic IPF in vivo as well as in vitro. ASV-IV alleviated levels of inflammatory cytokines and fibrosis markers in IPF model. Through detection of autophagy-related genes, ASV-IV was observed to induce autophagy in IPF. Besides, ASV-IV inhibited miR-21 expression in IPF models, and overexpression of miR-21 could reverse the protective potential of ASV-IV on IPF. PTEN was targeted by miR-21 and was up-regulated by ASV-IV in IPF models. In addition, levels of inflammatory cytokines and fibrosis markers, autophagy, as well as the PI3K/AKT/mTOR pathway regulated by ASV-IV could be neutralized after treatment with autophagy inhibitors, miR-21 mimics, or si-PTEN. Our study demonstrates that ASV-IV inhibits IPF through activation of autophagy by miR-21-mediated PTEN/PI3K/AKT/mTOR pathway, suggesting that ASV-IV could be acted to be a promising therapeutic method for IPF.